[ad_1]
London: British drug discovery company C4X Discovery said AstraZeneca had signed a license worth up $402 million to develop an oral therapy for the treatment of inflammatory and respiratory diseases using its NRF2 Activator programme.
C4XD said on Monday it would receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial, including $2 million upfront.
In addition, C4XD said it would receive a further potential $385.8 million in clinical development and commercial milestones and tiered mid-single digit royalties upon commercialisation of any treatment.
[ad_2]
Source link